Bleomycin Etoposide and Cisplatin

Phase 3Small molecule

SSt. Olavs Hospital

Bleomycin Etoposide and Cisplatin is one of 5 small molecule programs targeting Seminoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SeminomaActive, not recruiting

SeminomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Seminoma

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

4 2

Jevtana

Sanofi

Phase 2

1 3

Vepesid

AAvyxa

Phase 2

2 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 5

Bleomycin Etoposide and Cisplatin

SSt. Olavs Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 3Active, not recruiting

Seminoma

NCT02341989

Clinical

Trials by Indication[1]

Seminoma1 trial

Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer

Active, not recruiting·SSt. Olavs Hospital·Phase 3·NCT02341989·348 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bleomycin Etoposide and Cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bleomycin Etoposide and Cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bleomycin Etoposide and Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Olavs Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSt. Olavs Hospital

Bleomycin Etoposide and Cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Seminoma1 trial

References

Drug Info

Quick Facts

Related News